Market Overview
Any component or portion of blood that is harvested from a donor for use in patients is referred to as a blood product. Not every patient requires complete blood transfusion; many simply require transfusion of certain blood components. Several blood components are isolated from the total blood in such circumstances. Platelets, red blood cells (RBCs), white blood cells (WBCs), fresh frozen plasma (FFP), clotting factors, and other blood products are among the blood products available. An individual is given a specific blood product depending on their condition. Blood is an extremely important bodily fluid that ensures the proper functioning of organs. However, there are a variety of chronic medical problems that cause the body’s red blood cell count to drop. Diseases like leukemia, cancer, and end-stage renal disease, for example, cause significant consequences that necessitate blood transfusions.
Blood Products Market: Key Players
Abbott Laboratories
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
American Red Cross
America`s Blood Centers
BPL Inc.
CSL
Mitsubishi Tanabe Pharma Corporation
Bharat Serums and Vaccines Ltd.
Bio Products Laboratory Ltd.
Kedrion S.p.A
Bio-Rad Laboratories, Inc.
Octapharma AG
Canadian Blood Services

Growth Factor
Rise in geriatric population
According to the World Health Organization, the worldwide population of people aged 60 and over will nearly double from 12 percent to 22 percent between 2015 and 2050, with 80 percent of the aging population residing in low- and middle-income nations. The world’s ageing population may result in a rise in illnesses that require plasma treatment. As a result, the market will develop faster as the senior population grows.
Segmentation
By Product Type
Platelets
Fresh Frozen Plasma (FFP)
Red Blood Cells (RBCs)
White Blood Cells (WBCs)
Others
By End-User
Hospitals
Blood Station
Others
Blood Products Market Dynamics
Blood Products Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints

Recent News Related to Market
North America is the market leader for blood plasma products, accounting for 44.2 percent of the market in 2018. This is owing to the increased prevalence of hemophilia and the FDA’s quick approval of plasma products.
In October 2018, The FDA revised its criteria on dried plasma products for blood transfusion, including everything from the best sources of input plasma to device submissions.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Blood Products Market growth?
Which segment accounted for the largest Blood Products Market share?
Who are the key players in the Blood Products Market?
Historical, current, and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint

Note: Although care has been taken to maintain the highest levels of accuracy in Our reports, recent market/vendor-specific changes may take time to reflect in the analysis.

The post Blood Products market : Global Analysis of Market Size, Share & Trends for 2019–2020 and Forecasts to 2030 first appeared on CRI Report.

According to CRI’s market research, the sales value of rhTPO in the Chinese market has increased year by year from 2016 to 2020. In 2020, due to the impact of the COVID-19 epidemic on the overall diagnosis and treatment services of hospitals in China, its sales growth has slowed, but the sales value of rhTPO in the Chinese market still reached CNY1.3 billion, and the CAGR was 32.44% in 2016 to 2020.

CRI expects that with the effective relief of the COVID-19 epidemic in 2021-2025, the sales of rhTPO will increase. In addition, the cancer incidence rate in China has maintained an annual increase of about 3.9% in the past 10 years. Therefore, the sales volume of rhTPO used to treat cancer and other chemotherapy-induced thrombocytopenia will increase with the increase in the number of cancer patients. At the same time, TPIAO’s patent has expired, and many companies in China have applied for approval for clinical trials of generic drugs. It is expected that new manufacturers will join the rhTPO market in the next five years, and sales will grow in the future.

Topics Covered:
-The impact of COVID-19 on China’s Recombinant Human Thrombopoietin(rhTPO) market
– Sales value of China’s Recombinant Human Thrombopoietin(rhTPO) 2016-2020
– Competitive landscape of China’s Recombinant Human Thrombopoietin(rhTPO) market
– Prices of Recombinant Human Thrombopoietin(rhTPO) in China
– Prices of Recombinant Human Thrombopoietin(rhTPO) in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Recombinant Human Thrombopoietin(rhTPO) market
– Prospect of China’s Recombinant Human Thrombopoietin(rhTPO) market from 2021 to 2025

The post Investigation Report on China’s Recombinant human thrombopoietin (rhTPO) Market 2021-2025 first appeared on CRI Report.

Due to the high demand for HSA in the Chinese market, it has become one of the blood products that China allows to import from restricted countries. Currently, there are over 30 manufacturers in the Chinese HSA market. The major manufacturers are Grifols, Baxter, CSL Behring, Aventis Behring, and Shandong Taibang. Among them, Grifols accounts for the largest market share. In 2020, it took about 22.57% of the total market sales.

According to CRI’s market research, the sales revenue of HSA in the Chinese market increased from CNY2.96 billion in 2016 to CNY4.22 billion in 2020. In 2020, the annual growth rate was 11.3%, which slowed down compared to that in 2019 due to the COVID-19 epidemic. The CAGR of sales value of Human Serum Albumin in China is 9.3% in 2016 to 2020. CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of HSA will have a recovery growth from 2021 to 2025.

Topics Covered:
-The impact of COVID-19 on China’s Human Serum Albumin market
– Sales value and volume of China’s Human Serum Albumin 2016-2020
– Competitive landscape of China’s Human Serum Albumin market
– Prices of Human Serum Albumin in China
– Prices of Human Serum Albumin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Human Serum Albumin market
– Prospect of China’s Human Serum Albumin market from 2021 to 2025

The post Investigation Report on China’s Human Serum Albumin Market 2021-2025 first appeared on CRI Report.